BiomX (PHGE) Operating Income (2018 - 2026)
BiomX (PHGE) posted Operating Income of -$1.3 million for Q1 2026, up 92.69% sequentially from -$17.7 million in Q4 2025, and up 83.29% YoY from -$707074.8 in Q1 2025.
BiomX (PHGE) Operating Income (2018 - 2026) Analysis & Trends
BiomX has reported Operating Income for 9 years, with the latest figure at -$1.3 million in Q1 2026.
- Quarterly Operating Income rose 83.29% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.0 million (up 23.05% YoY) and the FY2025 annual result came in at -$41.5 million, up 6.87% from the prior year.
- Operating Income advanced to -$1.3 million in Q1 2026 per PHGE's latest filing, from -$17.7 million in the prior quarter.
- Over five years, Operating Income peaked at -$1.3 million in Q1 2026 and troughed at -$17.7 million in Q4 2025.
- A 5-year average of -$8.3 million and a median of -$7.6 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2026: Operating Income plunged 216.48% in 2024, then jumped 83.29% in 2026.
- Over 5 years, Operating Income stood at -$5.6 million in 2022, then gained by 5.18% to -$5.3 million in 2023, then slumped by 216.48% to -$16.7 million in 2024, then fell by 6.33% to -$17.7 million in 2025, then soared by 92.69% to -$1.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.3 million, -$17.7 million, and -$8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | BiomX | 362,449.94 | -805,550.06 | - | -1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | -17.74 Mn |
| Sep 30, 2025 | -8.54 Mn |
| Jun 30, 2025 | -7.43 Mn |
| Mar 31, 2025 | -7.76 Mn |
| Dec 31, 2024 | -16.69 Mn |
| Sep 30, 2024 | -11.33 Mn |
| Jun 30, 2024 | -9.73 Mn |
| Dec 31, 2023 | -5.27 Mn |
| Sep 30, 2023 | -7.80 Mn |
| Jun 30, 2023 | -6.07 Mn |
| Mar 31, 2023 | -6.21 Mn |
| Dec 31, 2022 | -5.56 Mn |
| Sep 30, 2022 | -6.55 Mn |
| Jun 30, 2022 | -7.32 Mn |
| Mar 31, 2022 | -7.79 Mn |
| Dec 31, 2021 | -9.79 Mn |
| Sep 30, 2021 | -9.83 Mn |
| Jun 30, 2021 | -7.30 Mn |
| Mar 31, 2021 | -8.54 Mn |